Since the 2002 launch of Humira, many products have entered the rheumatoid arthritis (RA) market, but the majority of sales still belongs to the big three anti-TNFs (Enbrel, Humira and Remicade).

With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira holds a wide range of indications, but biosimilar versions of the drug led to price erosion beginning in 2023 and ...

as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug that is now facing stiff competition.

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

Quarterly sales of Humira declined 49% to $1.68 billion, a steeper fall than the $1.99 billion analysts expected, according to data compiled by LSEG. Once the world's best-selling drug, Humira must ...

(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship ...